Particle.news
Download on the App Store
5 ARTICLES
·
2d ago

France Suspends Chikungunya Vaccine for Seniors After Serious Adverse Events

Vaccination halted for those 65 and older in La Réunion and Mayotte following three severe reactions, including one death, as authorities refine epidemic response.

Le bilan provisoire de l'épidémie de chikungunya à La Réunion est de neuf morts, selon les autorités sanitaires.
Image
Image

Overview

  • French health authorities have suspended the Ixchiq vaccine for individuals aged 65 and over in La Réunion and Mayotte after three serious adverse events in patients over 80, including one death.
  • Vaccination remains available for individuals aged 18 to 64 with comorbidities, as the epidemic continues to impact the region significantly.
  • The Direction générale de la santé (DGS) requested an urgent reevaluation of vaccination guidelines from the Haute Autorité de santé (HAS), which recommended narrowing the target group for vaccination.
  • The chikungunya outbreak in La Réunion has caused nine confirmed deaths, with transmission stabilizing at high levels and underreporting suggesting up to 100,000 infections.
  • Ixchiq, developed by Valneva, is the first chikungunya vaccine authorized in Europe, highlighting the challenges of balancing rapid epidemic response and patient safety.